If you have tried antidepressants that did not work, or you would rather avoid medication altogether, you are not short on options. The harder question is which non-medication treatments actually have clinical data behind them, and how strong that data is.
We reviewed the peer-reviewed literature, FDA records, and expert consensus statements to rank the most common non-medication approaches for depression by the strength of their evidence. The short version: transcranial magnetic stimulation (TMS) therapy for depression currently sits at the top of the evidence hierarchy, followed by cognitive behavioral therapy (CBT) and ketamine, with exercise and mindfulness-based approaches showing more limited (but still real) benefits.
Here is how we organized that evidence, and what it means for your decision.
How we ranked these treatments
Not all clinical evidence carries the same weight. A single small study means something different than a multi-site randomized controlled trial (RCT) replicated over decades. We used three criteria:
Regulatory status: Has the treatment received FDA clearance or approval for depression?
Trial quality: How many RCTs exist, how large are the sample sizes, and were sham or placebo controls included?
Long-term data: Is there follow-up beyond the initial treatment period, ideally 1-5+ years?
These criteria give us three tiers. Treatments in higher tiers are not necessarily “better” for every person, but they have more rigorous evidence backing their use.
Tier 1: TMS therapy for depression
Transcranial magnetic stimulation is the only non-medication depression treatment that is both FDA-cleared and supported by extensive RCT data with long-term follow-up.
The evidence base is substantial. A 2025 consensus review published in Clinical Neurophysiology, endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology, examined nearly 2,400 studies. The panel confirmed that TMS is safe and effective for depression, including treatment-resistant cases. In real-world clinical settings, up to 83% of patients showed improvement and more than half achieved full remission, according to the review authors (Trapp et al., 2025).
Controlled trial data is more conservative but still strong. Sham-controlled RCTs show response rates of 50-60% (meaning at least 50% symptom reduction) and remission rates around 30% in the most rigorous designs. Those numbers compare favorably to standard antidepressants, which show roughly 20-30% placebo-adjusted response rates in treatment-resistant populations.
In March 2024, the FDA expanded clearance for the NeuroStar Advanced Therapy System to include adolescents aged 15 and older, based on registry data from over 1,100 adolescents showing a 59% response rate and 30% remission rate on the PHQ-9 symptom scale (with broader clinical improvement reported in up to 78% of patients on other assessment measures). Five-year follow-up data for adults shows sustained benefits, giving TMS the longest durability record among non-medication approaches.
Deep TMS, which uses H-coils to reach broader brain areas, received its own FDA clearance for depression in 2013 and has since been expanded to adolescent populations. Newer protocols like intermittent theta burst stimulation (iTBS) can deliver a full session in about three minutes, with equivalent results to standard 37-minute protocols.
For a deeper look at how the treatment works and what sessions are like, see our guide to TMS therapy for depression.
Tier 2: CBT and ketamine
Both cognitive behavioral therapy and ketamine have meaningful clinical evidence, though each comes with real-world limitations that keep them below TMS in our ranking.
CBT: effective but access-dependent
CBT is the most studied psychotherapy for depression, with over 20 RCTs showing response rates around 40% and remission rates of 30-40%. A 2022 meta-analysis of 28 RCTs (3,938 participants) found that CBT reduced the risk of depressive relapse by 27% compared to control treatments (Chen et al., Journal of Affective Disorders, 2022).
The real-world challenge is access and completion. Meta-analyses of CBT dropout rates in clinical settings report averages of 15-26% in controlled trials, but broader psychotherapy dropout meta-analyses show rates as high as 47% depending on how dropout is defined. In cities like New York, quality CBT therapists often have 3-4 month waitlists, and the typical course runs 16-20 weeks. The treatment works when people complete it, but many do not.
Ketamine: rapid but time-limited
IV ketamine (an anesthetic agent used off-label for depression) produces some of the fastest antidepressant responses in psychiatry, often within hours to days rather than weeks. Acute response rates of 60-70% have been reported in clinical studies. A systematic review in the Journal of Affective Disorders notes that single infusions can produce meaningful reductions in depressive symptoms within hours, contrasting with the delayed onset of conventional antidepressants.
The limitation is duration. Without ongoing maintenance, relapse is common after an initial ketamine course, with published estimates ranging from 30 to 50% depending on the study population and follow-up period. Ketamine also remains off-label for depression (esketamine, or Spravato, has FDA approval but is a different formulation with its own protocol), which means less standardized long-term safety data compared to TMS. Most published safety data covers 1-2 years, whereas TMS has 5+ years of follow-up.
For people experiencing severe depression with suicidal ideation, ketamine’s rapid onset can be genuinely life-saving. At Nushama, we offer IV ketamine under medical supervision with preparation and integration support because the medicine works best as part of a broader therapeutic framework, not a standalone intervention.
Tier 3: exercise and mindfulness-based therapy
Exercise and mindfulness-based cognitive therapy (MBCT) both have evidence supporting their use, but with important caveats about severity and effect size.
Exercise
A 2024 network meta-analysis published in The BMJ by Noetel et al. reviewed over 200 RCTs and found that exercise was comparable to psychotherapy and antidepressants for non-severe depression. Walking, jogging, yoga, and strength training all showed benefits, with more vigorous exercise producing stronger effects.
The catch: these benefits were clearest in mild-to-moderate depression. For severe or treatment-resistant cases, exercise alone is generally insufficient. The treatment also requires sustained lifestyle adherence, and dropout rates from exercise RCTs in people with MDD average about 18%, according to a meta-analysis published in Clinical Psychology Review.
Mindfulness-based cognitive therapy
MBCT combines CBT principles with meditation practices. A 2023 meta-analysis in Clinical Psychology Review comparing MBCT head-to-head with CBT across 30 RCTs and 2,705 participants found the two approaches were statistically equivalent in treating current depression.
Where MBCT shows its clearest strength is relapse prevention. A 2025 systematic review in the Journal of Affective Disorders Reports confirmed that MBCT, when combined with standard pharmacological treatment, reduces relapse rates and helps regulate rumination and emotion. For people who have recovered from depression and want to reduce their chances of recurrence, MBCT can be a useful addition to their toolkit.
Which non-medication treatment fits your situation
The strongest treatment for you depends on severity, urgency, and what you can access.
| Situation | Consider first | Why |
|---|---|---|
| Severe or treatment-resistant depression | TMS or IV ketamine | Strongest response rates; ketamine for acute crisis, TMS for durable relief |
| Moderate, chronic depression | TMS or intensive CBT | Both have solid trial data; TMS is faster to start in most cities |
| Mild depression | CBT or structured exercise | Lower-intensity approaches with meaningful evidence |
| Relapse prevention | MBCT or maintenance TMS | Evidence for reducing recurrence after initial recovery |
When you can expect to feel different
Treatment timelines vary, and these are general patterns, not guarantees:
IV ketamine: Some symptom relief within days. Peak effect around day 3-7. Maintenance sessions typically needed to sustain gains.
TMS: Most people notice changes around weeks 2-4 of a 4-6 week protocol. Effects can be durable for months to years.
CBT: Gradual improvement typically becomes noticeable around weeks 8-16 of a 16-20 week course.
Exercise: Benefits may appear within 2-4 weeks of consistent activity, but require ongoing commitment.
The bottom line on non-medication depression treatment
Evidence quality matters because it protects you. Treatments with large, well-controlled trials and long-term follow-up reduce the risk of spending time and money on something that does not work for your situation. TMS has the deepest evidence base among non-medication approaches. Ketamine and CBT are strong options with specific trade-offs. Exercise and mindfulness-based therapies can play a supporting role, particularly for milder symptoms or maintenance.
None of these approaches works in isolation for everyone. The most effective plans often combine treatments: TMS paired with therapy, or ketamine supported by preparation and integration work.
If you are weighing your options and want help figuring out what makes sense for your situation, speak with our care team to discuss what the evidence suggests for your specific needs.
FAQs
Does TMS work for depression?
Yes. TMS is FDA-cleared for depression and supported by extensive clinical trial data. A 2025 consensus review of nearly 2,400 studies confirmed its safety and effectiveness, with real-world remission rates exceeding 50% and controlled-trial remission rates around 30%. Response rates (at least 50% symptom reduction) range from 50-60% in sham-controlled studies.
What is the difference between TMS and deep TMS?
Standard TMS uses a figure-eight coil to target specific brain areas close to the scalp surface. Deep TMS uses H-coils to stimulate broader, deeper brain regions. Both are FDA-cleared for depression. Newer protocols like iTBS deliver equivalent results in shorter sessions, sometimes as little as three minutes.
Is ketamine or TMS better for depression?
It depends on your situation. Ketamine works faster (days vs. weeks) and may be more appropriate when someone needs urgent relief, such as during a suicidal crisis. TMS has stronger long-term durability data and FDA clearance specifically for depression. Some people benefit from both: ketamine for acute stabilization, followed by TMS for sustained improvement.
How much does non-medication depression treatment cost?
Costs vary by treatment and location. TMS typically runs $6,000-$12,000 for a full course, and some insurance plans now cover it. CBT costs $2,000-$5,000 for a 16-20 week course depending on therapist rates. IV ketamine ranges from $400-$800 per infusion, with a typical initial course of 4-6 infusions. Exercise-based programs vary widely but are generally the least expensive option.
